Cytochrome P450 Oxidase Inhibitors and Uses Thereof
申请人:Klein Larry L.
公开号:US20080161246A1
公开(公告)日:2008-07-03
The present invention features compounds of formula I
or pharmaceutically acceptable salts, solvates or prodrugs thereof, and methods of using the same to inhibit the metabolizing activities of CYP enzymes. The present invention also features methods of using these compounds, salts, solvates or prodrugs to improve the pharmacokinetics of drugs that are metabolized by CYP enzymes.
CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF
申请人:Klein Larry L.
公开号:US20120083490A1
公开(公告)日:2012-04-05
The present invention features compounds of formula I
or pharmaceutically acceptable salts, solvates or prodrugs thereof, and methods of using the same to inhibit the metabolizing activities of CYP enzymes. The present invention also features methods of using these compounds, salts, solvates or prodrugs to improve the pharmacokinetics of drugs that are metabolized by CYP enzymes.
Cytochrome P450 oxidase inhibitors and uses thereof
申请人:Abbott Laboratories
公开号:EP2465855A1
公开(公告)日:2012-06-20
The present invention features compounds of formula (I) or pharmaceutically acceptable salts, solvates thereof, and compounds of formula (I) for use in inhibiting the metabolizing activities of CYP enzymes. The present invention also features compounds of formula (I) for use in improving the pharmacokinetics of drugs that are metabolized by CYP enzymes.
[EN] CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DES OXYDASES P450 DE CYTOCHROME ET UTILISATION DE CES DERNIERS
申请人:ABBOTT LAB
公开号:WO2008027932A2
公开(公告)日:2008-03-06
[EN] The present invention features compounds of formula I or pharmaceutically acceptable salts, solvates or prodrugs thereof, and methods of using the same to inhibit the metabolizing activities of CYP enzymes. The present invention also features methods of using these compounds, salts, solvates or prodrugs to improve the pharmacokinetics of drugs that are metabolized by CYP enzymes. [FR] La présente invention concerne des composés représentés par la formule I ou des sels, des solvates ou des promédicaments pharmaceutiquement acceptables de ces composés et des procédés d'utilisation de ces derniers pour inhiber les activités de métabolisation des enzymes CYP. Cette invention porte également sur des procédés d'utilisation de ces composés, ces sels, ces solvates ou ces promédicaments pour améliorer la pharmacocinétique des médicaments qui sont métabolisés par les enzymes CYP.